Differential regulation of MAPK (JNK 3) gene expression in human head and neck squamous cell carcinomas

Onkologie

Volumn 27, Issue 4, 2004, Pages 353-357

  Gorogh T ^a   Berwig, J ^a   Scola, N ^a   Lippert, B M ^b,c  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Gene expression; Head and neck carcinomas; Mitogen activated protein kinase

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE;

ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; CARCINOMA CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DATA BASE; ELECTROPHORESIS; FEMALE; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYBRIDIZATION; INTESTINE MUCOSA; KERATINOCYTE; MALE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PHENOTYPE; RNA EXTRACTION; RNA FINGERPRINTING; SEQUENCE HOMOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; DNA FINGERPRINTING; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 10; NEOPLASM STAGING; OTORHINOLARYNGOLOGIC NEOPLASMS; PROGNOSIS; RESPIRATORY MUCOSA; RNA, MESSENGER; SEQUENCE HOMOLOGY;

EID: 4644242351     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079087     Document Type: Article

References (36)

1. Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54:594-606.
2. Moisa II, Mahdevia P, Silver CE: Unusual tumors of the larynx; in Silver CE (ed): Laryngeal Cancer. New York, Thieme, 1991, pp 33-43.
3. Blitzner PH: Epidemiology of the head and neck cancer. Semin Oncol 1988;15:2-9.
4. Moore C: Cigarette smoking and cancer of the mouth, pharynx, and larynx. A continuing study. JAMA 1971;218:553-558.
5. Bofetta P, Merletti F, Faggiano F, Migliaretti G, Ferro G, Zanetti R, Terracini B: Prognostic factors and survival of laryngeal cancer patients from Turin, Italy. A population-based study. Am J Epidemiol 1997;145:1100-1005.
6. Gillison ML, Koch WM, Shah KV: Human papilloma virus in head and neck squamous cell carcinoma: Are some head and neck cancers a sexually transmitted desease? Curr Opin Oncol 1999;11:191-199.
7. van Houten VM, Snijders PJ, van den Brekel MW, Kummer JA, Meijer CJ, van Leeuwen B, Denkers F, Smeele LE, Snow GB, Brakenhoff RH: Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cellcarcinomas. Int J Cancer 2001;93:232-235.
8. Lewin F, Norell SE, Johansson H, Gustavsson P, Wennerberg J, Biorklund A, Rutquist LE: Smoking tobacco, oral snuff, and alcohol in the etiology of sqamous cell carcinoma of the head and neck: A population-based case-referent study in Sweden. Cancer 1998;82:1367-1375.
9. Carey TE: Head and neck tumor cell lines; in Hay RJ, Park JG, Gazdar A (eds): Atlas of Human Tumor Cell Lines. San Diego, Academic Press, 1994, pp 79-117.
10. Elomaa L, Joensuu H, Kulmala J, Klemi P, Grenman R: Squamous cell carcinoma is highly sensitive to taxol, a possible new radiation sensitizer. Acta Otolaryngol 1995;115:340-344.
11. Saffran S, Görögh T, Lippert BM, Werner JA: Cultivation of human keratinocytes of mucous membranes of the upper aerodigestiv tract. Laryngorhinootologie 1997;76:101-105.
12. Russell WC, Newmann C, Williamson DH: A simple technique for demonstration of DNA in cells infected with mycoplasma and viruses. Nature 1975;253:461-462.
13. Liang P, Pardee AB: Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 1992;257:967-971.
14. Sambrook J, Fritsch EF, Maniatis T (eds): Molecular Cloning, ed 2. New York, Cold Spring Harbor, 1989.
15. Rincon M, Whitmarsh A, Yang DD, Weiss L, Derijard B, Jayaraj P, Davis RJ, Flavell RA: The JNK pathway regulates the in vivo deletion of immature CD4(+)CD8(+) thymocytes. J Exp Med 1998;188:1817-1830.
16. Ham J, Eilers A, Whitfield J, Neame SJ, Shah B: c-Jun and the transcriptional control of neuronal apoptosis. Biochem Pharmacol 2000;60:1015-1021.
17. Lamb JA, Ventura JJ, Hess P, Flavell RA, Davis RJ: JunD mediates survival signaling by the JNK signal transduction pathway. Mol Cell 2003;11:1479-1489.
18. Yang DD, Kuan CY, Whitmarsh AJ, Rincon M, Zheng TS, Davis RJ, Rakic P, Flavell RA: Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk 3 gene. Nature 1997;389:865-870.
19. Bruckner SR, Tammariello SP, Kuan CY, Flavell RA, Rakic P, Estus S: JNK 3 contributes to c-Jun activation and apoptosis but not oxidative stress in nerve growth factor-deprived sympathetic neurons. J Neurochem 2001;78:298-303.
20. Bruckner SR, Estus S: JNK 3 contributes to c-jun induction and apoptosis in 4-hydroxynoneal-treated sympathetic neurons. J Neurosci Res 2002;70:665-670.
21. Jurewicz A, Matysiak M, Tybor K, Selmaj K: TNF-induced death of adult oligodendrocytes is mediated by c-Jun NH2-terminal kinase-3. Brain 2003;126:1358-1370.
22. Smeal T, Binetruy B, Mercola DA, Birrer M, Karin M: Oncogenic and transcriptional cooperation with Ha-Ras requires phosporylation of c-Jun on Serines 63 and 73. Nature 1991;354:494-496.
23. Johnson R, Spiegelman B, Hanahan D, Wisdom R: Cellular transformation and malignancy induced by ras require c-jun. Mol Cell Biol 1996;16:4504-4511.
24. Bost F, McKay R, Bost M, Potapova O, Dean NM, Mercola D: The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells. Mol Cell Biol 1999;19:1938-1949.
25. Antonyak MA, Moscatello DK, Wong AJ: Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J Biol Chem 1998;273:2817-2822.
26. Behrens A, Jochum W, Sibilia M, Wagner EF: Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation. Oncogene 2000;19:2657-2663.
27. Potapova O, Gorospe M, Bost F, Dean NM, Gaarde WA, Mercola D, Holbrook NJ: c-Jun N-terminal kinase is essential for growth of human T98G glioblatoma cells. J Biol Chem 2000;275:24767-24775.
28. Antonyak MA, Kenyon LC, Godwin AK, James DC, Emlet DR, Okamoto I, Tnani M, Holgado-Madruga M, Moscatello DK, Wong AJ: Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene 2002;21:5038-5046.
29. Yang YM, Bost F, Charbono W, Dean N, McKay R, Rhim JS, Depatie C, Mercola D: C-Jun NH(2)-terminal kinase mediates proliferation and tumor growths of human prostata carcinoma. Clin Cancer Res 2003;9:391-401.
30. Potapova O, Anisimov SV, Gorospe M, Dougherty RH, Gaarde WA, Boheler KR, Holbrook NJ: Targets of c-Jun NH(2)-terminal kinase 2-mediated tumor growth regulation revealed by serial analysis of gene expression. Cancer Res 2002;62:3257-3263.
31. Kennedy NJ, Davis RJ: Role of JNK in tumor development. Cell Cycle 2003;2:199-201.
32. Yoshida S, Fukino K, Harada H, Nagai H, Imoto I, Inazawa J, Takahashi H, Teramoto A, Emi M: The c-Jun NH2-terminal kinase 3 (JNK 3) gene: Genomic structure, chromosomal assignment, and loss of expression in brain tumors. J Hum Genet 2001;46:182-187.
33. Masuda M, Toh S, Koike K, Kuratomi Y, Suzui M, Deguchi A, Komiyama S, Weinstein IB: The roles of JNK 1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil. Jpn J Cancer Res 2002;93:329-339.
34. Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, Manning AM, Firestein GS: c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001;108:73-81.
35. Boyczenko-Coyne D, Saporito MS, Hudkins RL: Targeting the JNK pathway for therapeutic benefit in CNS disease. Curr Drug Target CNS Neurol Disord 2002;1:31-49.
36. Hidding U, Mielke K, Wätzig V, Brecht S, Hanisch U, Behrens A, Wagner E, Herdegen T: The c-Jun N-terminal kinases in cerebral microglia: Immunological functions in the brain. Biochem Pharmacol 2002;64:781-788.